China NMPA Product Recall - Programmable Drug Infusion System

The National Medical Products Administration (NMPA) issued a notification on November 4, 2024, concerning a voluntary Class II recall initiated by Medtronic Inc. This action was reported to the NMPA by Medtronic (Shanghai) Management Co., Ltd. and involves specific Programmable Drug Infusion Systems, registered under National Medical Device Registration Certificate No. 20173125069. The central issue necessitating this recall is the identified inability of these drug infusion systems to effectively perform crucial reperfusion and programmed operations. This operational deficiency poses potential risks related to the accurate and timely delivery of medication, which could compromise patient care. The company has taken this proactive measure to address these performance concerns, underscoring its commitment to product reliability and patient safety standards. It is important to note that the particular models, specifications, and batches of products implicated in this recall were not imported into the Chinese market. Consequently, this recall primarily impacts other global regions where these devices were distributed. The regulatory oversight by the NMPA highlights the comprehensive approach to medical device safety, even for products not directly circulated within China. Further comprehensive details regarding the specific recalled devices are contained within the "Medical Device Recall Event Report Form" attached to the official NMPA announcement. This voluntary recall exemplifies Medtronic's adherence to global quality management systems and responsiveness to product performance issues.